Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the writing committee of the American society for apheresis: the …

J Schwartz, A Padmanabhan, N Aqui… - Journal of clinical …, 2016 - Wiley Online Library
The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …

Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …

L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …

A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …

[HTML][HTML] Harnessing apoptotic cell clearance to treat autoimmune arthritis

P Saas, F Bonnefoy, E Toussirot… - Frontiers in …, 2017 - frontiersin.org
Early-stage apoptotic cells possess immunomodulatory properties. Proper apoptotic cell
clearance during homeostasis has been shown to limit subsequent immune responses …

[HTML][HTML] Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita …

CG Santi, AC Gripp, AM Roselino, DS Mello… - Anais brasileiros de …, 2019 - SciELO Brasil
Bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita
are subepidermal autoimmune blistering diseases whose antigenic target is located at the …

Extracorporeal photopheresis and the cellular mechanisms: Effects of 8‐methoxypsoralen and UVA treatment on red blood cells, platelets and reactive oxygen …

H Budde, L Mohr, I Bogeski, J Riggert… - Vox Sanguinis, 2023 - Wiley Online Library
Abstract Background and Objectives Extracorporeal photopheresis (ECP) is a widespread
cellular therapy for graft‐versus‐host disease, autoimmune diseases and Sézary disease …

Critical updates in the 7th edition of the American Society for Apheresis guidelines

TS Ipe, HP Pham, LA Williams III - Journal of Clinical Apheresis, 2018 - Wiley Online Library
The 7th edition of the American Society for Apheresis (ASFA) guidelines was composed by
an international physicians committee, and includes 14 new diseases, and 2 new …

Use of extracorporeal photopheresis in scleroderma: a review

AX Du, M Osman, R Gniadecki - Dermatology, 2020 - karger.com
Background: Scleroderma is a heterogeneous group of diseases that can be localized or
systemic. Localized scleroderma is a fibrosis of the skin characterized by inflammation and …

In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: new insights in extracorporeal photopheresis

C Coppard, D Hannani, M Humbert… - Journal of clinical …, 2019 - Wiley Online Library
Background Extracorporeal photopheresis (ECP) is an effective therapy for graft vs host
disease (GVHD), based on infusion of UVA‐irradiated and 8 methoxy‐psoralen (PUVA) …

Vascular access considerations for extracorporeal photopheresis

J Adamski - Transfusion, 2018 - Wiley Online Library
Extracorporeal photopheresis is an immunomodulatory therapy indicated for patients with
cutaneous T‐cell lymphoma, graft‐versus‐host disease, and heart or lung allograft rejection …